Neurocrine Biosciences, Inc.
NASDAQNBIX closed the week at $135.06, up 5.4% in five sessions, as a clean Q1 earnings release on May 5 triggered a wave of analyst target increases the following morning — a rare show of broad post-results conviction. The Street response was unusually coordinated. Six firms raised price targets on May 6, all maintaining their existing ratings, signalling that no one felt the need to…
Snapshot as of 6 May 2026
NBIX closed the week at $135.06, up 5.4% in five sessions, as a clean Q1 earnings release on May 5 triggered a wave of analyst target increases the following morning — a rare show of broad post-results conviction. The…
Neurocrine Biosciences heads into its May 5 Q1 results with a notable and accelerating build in short positions — the most distinctive feature of the current setup. Short interest has climbed sharply over the past…
Neurocrine Biosciences heads into its May 1 Q1 results with short sellers meaningfully more aggressive than they were just a month ago — and options traders turning cautious on the day before the release. The short…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NBIX — free to start on ORTEX.
Sign up for free →Open NBIX on ORTEX